Management of Thrombocytopenia in Patients on Rivaroxaban

Assessment and Management

For patients on rivaroxaban who develop thrombocytopenia, discontinue rivaroxaban and switch to a low molecular weight heparin (LMWH) with dose adjustments based on platelet count severity, as recommended by the International Society on Thrombosis and Haemostasis 1, 2
Evaluate the severity of thrombocytopenia by platelet count thresholds:
Discontinue rivaroxaban and switch to LMWH at reduced dose (50% of therapeutic dose or prophylactic dose) for patients with platelet count 25-50 × 10^9/L, as recommended by the European Society of Cardiology 1, 2
For patients with platelet count <25 × 10^9/L, discontinue all anticoagulation temporarily and consider platelet transfusion if there is active bleeding or high thrombotic risk, as recommended by the American Society of Hematology 1, 2, 3

For high thrombotic risk patients, consider therapeutic dose LMWH with platelet transfusion support to maintain platelet count >40-50 × 10^9/L, as recommended by the International Society on Thrombosis and Haemostasis 1, 2
For low thrombotic risk patients, reduced-dose strategy is preferred (50% or prophylactic-dose LMWH), as recommended by the American College of Chest Physicians 1, 4
If heparin-induced thrombocytopenia (HIT) is suspected, discontinue all heparin products and consider non-heparin anticoagulants such as argatroban, bivalirudin, danaparoid, or fondaparinux, as recommended by the American Society of Hematology 6

Monitor platelet count daily until stable or improving, as recommended by the International Society on Thrombosis and Haemostasis 3
When platelet count recovers to >50 × 10^9/L, reassess the need for continued anticoagulation, as recommended by the American College of Chest Physicians 1, 2
Consider alternative long-term anticoagulation options based on the underlying indication, as recommended by the European Society of Cardiology 2, 3